L.A. Mckeown

In high- and standard-risk patients CAS and TCAR look good, but some worry about skill sets, learning curves, and territorialism.

Compared with placebo, sodium zirconium cyclosilicate was associated with less need to lower or discontinue spironolactone.

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling inhibitor.

Lack of transparency in early studies and manufacturer summaries are among the issues uncovered during litigation.

A review article emphasizes optimizing GDMT and getting early referrals to better manage risks and weigh benefits.

The paper compares the current peripheral transradial trajectory to that of the coronary space in the mid-2000s.

The enhanced benefits seen for those with higher BMIs is in sync with growing interest in obesity-related HF.

Two pacing-dependent patients have died: an increased risk of permanently entering Safety Mode has been identified.

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.